Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Julie A Campbell, Steve Simpson-Yap, Bruce V Taylor, Ingrid van der Mei, Laura Laslett, Glen Henson, Ting Zhao, Andrew J Palmer
BACKGROUND: Multiple sclerosis (MS) prevalence is increasing globally. OBJECTIVES: To determine whether increased prevalence is continuing within Australia using our validated prescription-based ascertainment method. METHODS: We used methods employed in our 2010 and 2017 prevalence estimates. Disease-modifying therapy (DMT) prescriptions were extracted from Australia's Pharmaceutical Benefits Scheme data for January-December 2021. DMT penetrance was calculated using data from the Australian MS Longitudinal Study...
August 5, 2024: Multiple Sclerosis: Clinical and Laboratory Research
#22
JOURNAL ARTICLE
Michelle H Cameron, Andrea Hildebrand, Cinda Hugos, Lindsey Wooliscroft
BACKGROUND: People with multiple sclerosis (MS) fall frequently. Poor walking aid selection, fit, and use contribute to falls in those who use walking aids. OBJECTIVES: To determine if the Assistive Device Selection, Training, and Education Program (ADSTEP), with six weekly one-on-one virtual sessions with a physical therapist prevents falls and improves other outcomes in people with MS who use walking aids but still fall. METHODS: A total of 78 people were randomized to ADSTEP or control...
August 5, 2024: Multiple Sclerosis: Clinical and Laboratory Research
#23
JOURNAL ARTICLE
Emily Dvorak, Sarah Levy, Jordyn R Anderson, James F Sumowski
BACKGROUND: Word-finding difficulty is prevalent but poorly understood in persons with relapsing-remitting multiple sclerosis (RRMS). OBJECTIVE: The objective was to investigate our hypothesis that phonological processing ability is below expectations and related to word-finding difficulty in patients with RRMS. METHOD: Data were analyzed from patients with RRMS ( n = 50) on patient-reported word-finding difficulty (PR-WFD) and objective performance on Wechsler Individual Achievement Test, Fourth Edition (WIAT-4) Phonemic Proficiency (PP; analysis of phonemes within words), Word Reading (WR; proxy of premorbid literacy and verbal ability), and Sentence Repetition (SR; auditory processing of word-level information)...
August 5, 2024: Multiple Sclerosis: Clinical and Laboratory Research
#24
JOURNAL ARTICLE
Izanne Roos, Sifat Sharmin, Charles Malpas, Serkan Ozakbas, Jeannette Lechner-Scott, Suzanne Hodgkinson, Raed Alroughani, Sara Eichau Madueño, Cavit Boz, Anneke van der Walt, Helmut Butzkueven, Katherine Buzzard, Olga Skibina, Matteo Foschi, Francois Grand'Maison, Nevin John, Pierre Grammond, Murat Terzi, Julie Prévost, Michael Barnett, Guy Laureys, Liesbeth Van Hijfte, Jose Luis Sanchez-Menoyo, Yolanda Blanco, Jiwon Oh, Pamela McCombe, Cristina Ramo Tello, Aysun Soysal, Alexandre Prat, Pierre Duquette, Bassem I Yamout, Samia Khoury, Vincent van Pesch, Richard Macdonell, Maria José Sá, Mark Slee, Jens Kuhle, Davide Maimone, Daniele LA Spitaleri, Barbara Willekens, Abdallah Al Asmi, Emma Tallantyre, Neil P Robertson, Alasdair Coles, J William L Brown, Tomas Kalincik
BACKGROUND: Comparisons between cladribine and other potent immunotherapies for multiple sclerosis (MS) are lacking. OBJECTIVES: To compare the effectiveness of cladribine against fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting MS. METHODS: Patients with relapsing-remitting MS treated with cladribine, fingolimod, natalizumab, ocrelizumab or alemtuzumab were identified in the global MSBase cohort and two additional UK centres...
August 1, 2024: Multiple Sclerosis: Clinical and Laboratory Research
#25
JOURNAL ARTICLE
Bruce Bebo, Tim Coetzee, Emma Gray, Anne Helme, Pamela Kanellis, Douglas Landsman, Michaela Mai, Beatriz Martinez de la Cruz, Julia Morahan, Emmanuelle Plassart, Baylee Pickrell, Sarah Rawlings, Lasse Skovgaard, Paola Zaratin, Lindsay Rechtman
INTRODUCTION: Multiple sclerosis (MS) is an immune-mediated central nervous system disorder and a growing global health challenge affecting nearly 3 million people worldwide. Incidence and prevalence continue to increase with no known cause or cure. Globally governments and non-profit organizations fund research toward better understanding of and treatments for multiple sclerosis. METHODS: This study identified MS research projects funded between 2021 and 2023 by government and non-profit organization sources...
July 31, 2024: Multiple Sclerosis: Clinical and Laboratory Research
#26
JOURNAL ARTICLE
Luca Prosperini, Serena Ruggieri, Shalom Haggiag, Carla Tortorella, Claudio Gasperini
OBJECTIVE: To summarize the current evidence on relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA) through a quantitative synthesis of real-world studies. METHODS: Scientific databases were searched to identify suitable articles. Random-effects meta-analyses, subgroup analyses and meta-regression models were ran to provide pooled estimates of RAW and PIRA events and to identify their potential moderators (PROSPERO registration: CRD42024503895)...
July 31, 2024: Multiple Sclerosis: Clinical and Laboratory Research
#27
JOURNAL ARTICLE
Marina Romozzi, Catello Vollono, Paolo Calabresi, Raffaele Iorio
A 52-year-old man experienced two seizures in January and June 2021. In October, the neurological examination did not reveal sensory/motor deficits. Brain magnetic resonance imaging (MRI) showed hyperintense lesions with contrast enhancement (CE) involving white matter bilaterally, brainstem, and cerebellum. Spine MRI showed hyperintense C2-C3 and C4-C6 lesions with CE. Anti-aquaporin-4 (AQP4) antibodies were detected, confirming the diagnosis of neuromyelitis optica spectrum disorder (NMOSD). The patient experienced a status epilepticus compatible with Epilepsia Partialis Continua treated with antiseizure medications...
July 30, 2024: Multiple Sclerosis: Clinical and Laboratory Research
#28
JOURNAL ARTICLE
Giovanni Novi, Elvira Sbragia, Luana Benedetti, Angelo Schenone, Antonio Uccelli, Roberta Magliozzi, Massimo Del Sette, Matilde Inglese, Alice Laroni
OBJECTIVES: neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease mainly affecting optic nerves and the spinal cord. Due to the potentially irreversible tissue damage, prevention of relapses is of utmost importance. METHODS: We describe the atypical clinical course and pathology results of a patient with anti-aquaporin-4 antibody (anti-AQP4-Ab)-associated NMOSD who developed aseptic meningitis followed by limbic-encephalitis-like presentation with extensive brain lesions upon treatment with rituximab and tocilizumab...
July 30, 2024: Multiple Sclerosis: Clinical and Laboratory Research
#29
JOURNAL ARTICLE
Edgar Carnero Contentti
No abstract text is available yet for this article.
July 30, 2024: Multiple Sclerosis: Clinical and Laboratory Research
#30
JOURNAL ARTICLE
Maya Zeineddine, Raed Al-Roughani, Samar Farouk Ahmed, Samia Khoury, Nabil El-Ayoubi, Akram Al-Mahdawi, Jaber Al-Khabouri, Abdullah Al-Asmi, Amina Chentouf, Jihad Inshasi, Riadh Gouider, Saloua Mrabet, Nevin Shalaby, Joelle Massouh, Farah Mohamed Ramzy Hasan Mohamed, Amal Al-Hajje, Pascale Salameh, Hani Dimassi, Farid Boumediene, Bassem Yamout
INTRODUCTION: One strategy to mitigate progressive multifocal leukoencephalopathy (PML) risk is to switch to other highly effective disease-modifying therapies (DMTs). However, the optimal switch DMT following natalizumab (NTZ) discontinuation is yet to be determined. OBJECTIVE: The objective of the study is to determine the most effective and tolerable DMTs to switch to following NTZ discontinuation due to John Cunningham virus (JCV) antibody positivity. METHODS: This is a multicenter observational cohort study that included all stable relapsing-remitting multiple sclerosis (MS) patients who were treated with NTZ for at least 6 months before switching therapy due to JCV antibody positivity...
July 26, 2024: Multiple Sclerosis: Clinical and Laboratory Research
#31
JOURNAL ARTICLE
Nimreth Kaur Sidhu, Hannah Proudfoot, Hiba Mohammed Adan, Sophie Fawson, Rona Moss-Morris
No abstract text is available yet for this article.
July 26, 2024: Multiple Sclerosis: Clinical and Laboratory Research
#32
LETTER
Pernilla Stridh, Jesse Huang, Ingrid Kockum
No abstract text is available yet for this article.
July 26, 2024: Multiple Sclerosis: Clinical and Laboratory Research
#33
JOURNAL ARTICLE
Matthew Scaramozza, Patrizia A Chiesa, Lauren Zajac, Zhaonan Sun, Minao Tang, Adrien Juraver, Emmanuel Bartholomé, Julie Charré-Morin, Aurore Saubusse, Sterling C Johnson, Bruno Brochet, Loic Carment, Marta Ruiz, Nolan Campbell, Aurélie Ruet
BACKGROUND: The Konectom™ smartphone-based cognitive processing speed (CPS) test is designed to assess processing speed and account for impact of visuomotor function on performance. OBJECTIVE: Evaluate reliability and validity of Konectom CPS Test, performed in clinic and remotely. METHODS: Data were collected from people with multiple sclerosis (PwMS) aged 18-64 years and healthy control participants (HC) matched for age, sex, and education...
June 24, 2024: Multiple Sclerosis: Clinical and Laboratory Research
#34
JOURNAL ARTICLE
Melinda Magyari
No abstract text is available yet for this article.
June 22, 2024: Multiple Sclerosis: Clinical and Laboratory Research
#35
JOURNAL ARTICLE
All women with MS should start hormone replacement therapy at menopause unless contraindicated: Yes.
Rhonda Voskuhl
No abstract text is available yet for this article.
June 22, 2024: Multiple Sclerosis: Clinical and Laboratory Research
#36
JOURNAL ARTICLE
Kate Petheram, Ruth Dobson
No abstract text is available yet for this article.
June 22, 2024: Multiple Sclerosis: Clinical and Laboratory Research
#37
JOURNAL ARTICLE
William L Conte
Multiple sclerosis (MS) research has largely overlooked the experiences of the LGBTQ+ community, leaving significant gaps in understanding and addressing their unique health equity challenges. Despite widespread recognition of LGBTQ+ health disparities, particularly in neurology, research at the intersection of sexual orientation, gender identity, and MS remains limited. LGBTQ+ individuals encounter systemic barriers such as discrimination and lack of culturally competent care, exacerbating disparities in MS management and outcomes...
June 19, 2024: Multiple Sclerosis: Clinical and Laboratory Research
#38
JOURNAL ARTICLE
Monitoring cognitive functioning in multiple sclerosis will trigger anxiety in patients: Commentary.
Sarah A Morrow, Laura Hancock
No abstract text is available yet for this article.
June 16, 2024: Multiple Sclerosis: Clinical and Laboratory Research
#39
JOURNAL ARTICLE
Lauren Krupp, Kimberly A O'Neill
No abstract text is available yet for this article.
June 16, 2024: Multiple Sclerosis: Clinical and Laboratory Research
#40
JOURNAL ARTICLE
Martin Klein
No abstract text is available yet for this article.
June 16, 2024: Multiple Sclerosis: Clinical and Laboratory Research
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
